Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Laryngoscope ; 2024 Jul 06.
Article in English | MEDLINE | ID: mdl-38970445

ABSTRACT

BACKGROUND: The loss of laryngeal function affects breathing, swallowing, and voice, thus severely compromises quality of life. Laryngeal transplantation has long been suggested as a solution for selected highly affected patients with complete laryngeal function loss. OBJECTIVE: To obtain insights regarding the advantages, weaknesses, and limitations of this procedure and facilitate future advances, we collected uniform data from all known laryngeal transplants reported internationally. METHODOLOGY: A case series. Patients were enrolled retrospectively by each institutional hospital or clinic. Eleven patients with complete loss of laryngeal function undergoing total laryngeal transplantation between 1998 and 2018 were recruited. RESULTS: After a minimum of 24 months follow-up, three patients had died (27%), and there were two graft explants in survivors, one total and one partial, due to chronic rejection. In the remaining cases, voice was functional in 62.5% and 50% achieved decannulation. Swallowing was initially restricted, but only one patient was gastrostomy-dependent by 6 months and all had normal or near-normal swallowing by the end of year two after transplantation. Median follow-up was 73 months. Functional (voice, swallowing, airway) recovery peaked between 12 and 24 months. CONCLUSIONS: Laryngeal transplantation is a complex procedure with significant morbidity. Significant improvements in quality of life are possible for highly selected individuals with end-stage laryngeal disorders, including laryngeal neoplasia, but further technical and pharmacological developments are required if the technique is to be more widely applicable. An international registry should be created to provide better quality pooled data for analysis of outcomes of any future laryngeal transplants. LEVEL OF EVIDENCE: IV Laryngoscope, 2024.

2.
Nature ; 620(7975): 855-862, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37532930

ABSTRACT

Patients from historically under-represented racial and ethnic groups are enrolled in cancer clinical trials at disproportionately low rates in the USA1-3. As these patients often have limited English proficiency4-7, we hypothesized that one barrier to their inclusion is the cost to investigators of translating consent documents. To test this hypothesis, we evaluated more than 12,000 consent events at a large cancer centre and assessed whether patients requiring translated consent documents would sign consent documents less frequently in studies lacking industry sponsorship (for which the principal investigator pays the translation costs) than for industry-sponsored studies (for which the translation costs are covered by the sponsor). Here we show that the proportion of consent events for patients with limited English proficiency in studies not sponsored by industry was approximately half of that seen in industry-sponsored studies. We also show that among those signing consent documents, the proportion of consent documents translated into the patient's primary language in studies without industry sponsorship was approximately half of that seen in industry-sponsored studies. The results suggest that the cost of consent document translation in trials not sponsored by industry could be a potentially modifiable barrier to the inclusion of patients with limited English proficiency.


Subject(s)
Clinical Trials as Topic , Communication Barriers , Consent Forms , Drug Industry , Research Personnel , Translations , Humans , Consent Forms/economics , Translating , Clinical Trials as Topic/economics , Drug Industry/economics , Research Personnel/economics
3.
Food Res Int ; 169: 112861, 2023 07.
Article in English | MEDLINE | ID: mdl-37254435

ABSTRACT

The use of esterase/lipase enzymes of different origins in food industry is a widely employed strategy to enhance the formation of characteristic aromatic compounds derived from fat and diversify flavour. In the present work, we studied EstA enzyme of Enterococcus faecalis and a high purity Rhizomucor miehei lipase (Palatase). EstA was obtained recombinantly in Escherichia coli BL21 (DE3), and optimum esterase activity was detected at pH 6.75 and 40 °C. We evaluated the effect of the enzymes on milk mixtures prepared with different fat contents (2.8 and 6%) and structure (native or homogenized) on volatile compounds profiles. The milk fat structure before and after the application of low homogenization was characterized by dynamic light dispersion and microscopy. Native milk fat mixtures presented particles of 4.6 µm and 184 nm and homogenized mixtures had particles of 1.4 µm and 258 nm; microscopy images were in concordance with these results. Fifteen volatile compounds were identified, including ketones, esters, alcohols, and acids. We showed the key role of milk fat levels and microstructure in the nature of the volatile compounds produced by the R. miehei enzyme. Both in native or homogenized states, the highest content of fat favored a higher production of acids whereas the lowest fat level favored a higher esters production along with a more balanced volatile profile. For EstA enzyme, results showed a limited action on fat, as biosynthesis of esters only increased with the highest fat level homogenized.


Subject(s)
Enterococcus faecalis , Milk , Animals , Milk/chemistry , Lipase , Food Handling/methods , Esters/analysis
4.
Clin Cancer Res ; 29(4): 691-693, 2023 02 16.
Article in English | MEDLINE | ID: mdl-36520037

ABSTRACT

Immune checkpoint inhibitors have revolutionized the treatment of multiple solid malignancies, but their role in the treatment of neuroendocrine neoplasms (NEN) is unclear. The accompanying article reports on a study combining the programmed cell death (PD-1) inhibitor nivolumab with the alkylating agent temozolomide in patients with advanced NENs. See related article by Owen et al., p. 731.


Subject(s)
Neuroendocrine Tumors , Nivolumab , Humans , Nivolumab/therapeutic use , Temozolomide/therapeutic use , Neuroendocrine Tumors/pathology
5.
Cir Cir ; 90(S2): 23-28, 2022.
Article in English | MEDLINE | ID: mdl-36480756

ABSTRACT

INTRODUCTION: Zone I extensor tendon lesion accompanies an avulsion fracture of the bone insertion. A common complication of traditional pull-out is the necrosis of the site of the button in the finger pad. Zhang described an alternative way of anchoring the cerclage to the Kirschner Wire (K-wire) to relieve the pressure in the finger pad. He describes the use of wire cerclage, for fracture reduction. The objective of this paper is to perform a comparison between wire and nylon using Zhang pull-out technique. MATERIAL AND METHODS: We performed a cohort study comparing Nylon versus Wire in Zhang technique. Comparing cosmetic satisfaction, stiffness, residual pain, and Crawford scale. RESULTS: When comparing the outcomes between both groups, we found no statistical difference in cosmetic satisfaction (p = 0.285), stiffness (p = 0.460), and residual pain (p =1.000), overall complications (p = 1.000), or Crawford scale (p = 1.000). We only found a significant statistical difference in pain when removing the cerclage, being greater in Group B (p = 0.008). CONCLUSIONS: We found no significant outcome difference between nylon and wire cerclage. However, at the time of removing it, patients experience less pain.


INTRODUCCIÓN: Una complicación común del pull-put tradicional es la necrosis del sitio del botón en la yema del dedo. Zhang describió una forma alternativa de anclar el cerclaje al clavo de Kirschner para aliviar la presión en la yema del dedo. Describe el uso de cerclaje de alambre para la reducción de fracturas. El objetivo de este trabajo es realizar una comparación entre el alambre y el nailon utilizando la técnica de extracción de Zhang. MATERIAL Y MÉTODOS: Realizamos un estudio de cohorte comparando la técnica de nailon versus alambre en Zhang. Comparación de satisfacción cosmética, rigidez, dolor residual y escala de Crawford. RESULTADOS: Al comparar los resultados entre ambos grupos, no encontramos diferencias estadísticas en la satisfacción cosmética (p = 0.285), rigidez (p = 0.460) y dolor residual (p = 1.000), complicaciones generales (p = 1.000) o escala de Crawford (p = 1.000). Solo encontramos una diferencia estadística significativa en el dolor al retirar el cerclaje, siendo mayor en el Grupo B (p = 0.008). CONCLUSIONES: No encontramos diferencias significativas en los resultados entre el cerclaje de nailon y el cerclaje con alambre. Pero, al momento de retirarlo, los pacientes experimentan menos dolor. Tipo de estudio: terapéutico Nivel de evidencia III.


Subject(s)
Nylons , Pain , Humans , Cohort Studies
7.
Lung Cancer ; 161: 34-41, 2021 11.
Article in English | MEDLINE | ID: mdl-34507111

ABSTRACT

INTRODUCTION: Thyroid dysfunction is the most frequent endocrine immune related adverse event (irAE) in non-small cell lung cancer (NSCLC), typically arising 3-6 months into immune checkpoint inhibitor (ICI) therapy, but arising after ICI cessation, in some cases. Due to limited post-treatment adverse event reporting requirements on ICI trials, the incidence of ICI-induced thyroid dysfunction arising after therapy is unclear. We investigated ICI-induced thyroid dysfunction in a cohort of 294 NSCLC patients, with a specific focus on the post-treatment setting. METHODS: Retrospective analysis of ICI-induced thyroid dysfunction (clinically acted upon or laboratory only) was performed in 294 UCLA NSCLC patients treated 2012-2018. Clinically acted upon thyroid dysfunction was defined as thyroid diagnosis documentation and/or thyroid medication administration. Laboratory only dysfunction was defined as abnormal thyroid labs in the absence of clinical action. Timing of thyroid dysfunction relative to ICI treatment and thyroid monitoring patterns were also assessed. RESULTS: 82% (241/294) of ICI treated NSCLC patients had thyroid labs during treatment. Of these 241 patients, 13% (31/241) had clinically acted upon thyroid dysfunction prior to, 8% (18/241) during, and 4% (9/241) after ICI. Most patients, 66% (159/241), did not have thyroid labs after ICI, but in the 53 patients with labs and no prior clinical dysfunction, 17% (9/53) developed clinical dysfunction after ICI. In these 9 patients, median time from ICI initiation to dysfunction was 253 days. Two patients with post-treatment laboratory only dysfunction were observed. CONCLUSIONS: ICI-induced thyroid dysfunction arising post-treatment appears more common than previously appreciated, warranting additional evaluation.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Carcinoma, Non-Small-Cell Lung/drug therapy , Humans , Immune Checkpoint Inhibitors , Lung Neoplasms/drug therapy , Retrospective Studies , Thyroid Gland
9.
Rev. neurol. (Ed. impr.) ; 69(4): 145-151, 16 ago., 2019. tab, graf
Article in English | IBECS | ID: ibc-184072

ABSTRACT

Introduction. Psychogenic non-epileptic seizures (PNES) are paroxysmal changes in behavior that resemble epileptic seizures, although they have no electrophysiological correlation or clinical evidence of epilepsy. Aim. To compare clinical and sociodemographic characteristics of patients diagnosed with PNES-alone and PNES-andepilepsy. Patients and methods. A cross-sectional study of consecutive patients diagnosed with PNES in a 20-month period was carried out. A video-EEG was performed in all patients. Socio-demographical, clinical and semiological characteristics were compared between those patients with and without concomitant epilepsy. Results. Sixty-five patients were included, 35 (53.9%) had PNES-alone and 30 (46.1%) had PNES-and-epilepsy. The proportion of women in the study was 70.8%. The median age at seizure onset was 16 years. A late start was recorded in PNES-alone group (23 years) compared to PNES-and-epilepsy group (11 years), however, it was not significant. There was a lower frequency of antiepileptic drugs use in the PNES-alone group compared with the PNES-and-epilepsy group. The most frequent semiological features were the gradual onset of events (69.2%) and the duration longer than two minutes (63.1%). Conclusion. The waxing and waning pattern during paroxysmal events suggest a non-epileptic origin. However, it is not uncommon to find patients with concomitant epileptic seizures


Introducción. Las crisis psicógenas no epilépticas (CPNE) son cambios paroxísticos en el comportamiento que se asemejan a las crisis epilépticas, aunque no tienen correlación electrofisiológica ni evidencia clínica de epilepsia. Objetivo. Comparar las características clínicas y sociodemográficas entre pacientes diagnosticados con CPNE, con y sin epilepsia concomitante. Pacientes y métodos. Estudio transversal de pacientes consecutivamente diagnosticados de CPNE durante un período de 20 meses. A todos los participantes se les realizó un videoelectroencefalograma (video-EEG). Se compararon las características sociodemográficas, clínicas y semiológicas entre los que presentaban y los que no presentaban epilepsia concomitante. Resultados. Se incluyó a 65 pacientes, 35 con CPNE (53,9%), y 30 con CPNE y epilepsia (46,1%). La edad mediana en el inicio del video-EEG fue de 33 años, y un 70,8% eran mujeres. La edad mediana de inicio de las crisis fue de 16 años. En el grupo de CPNE hubo un inicio más tardío (23 años) en comparación con el grupo de CNPE y epilepsia (11 años), pero la diferencia no fue significativa. La proporción de pacientes en terapia con fármacos antiepilépticos fue significativamente mayor en el grupo con CPNE y epilepsia comparado con el grupo con CPNE. Las características semiológicas más frecuentemente encontradas fueron el inicio gradual de las crisis (69,2%) y una duración de más de dos minutos (63,1%). Conclusión. La variabilidad en los síntomas sugiere un origen no epiléptico de los eventos paroxísticos, los cuales se presentan frecuentemente en pacientes con epilepsia


Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Epilepsy/diagnosis , Cross-Sectional Studies , Diagnosis, Differential , Socioeconomic Factors , Colombia
10.
Immunotherapy ; 11(13): 1161-1176, 2019 09.
Article in English | MEDLINE | ID: mdl-31361169

ABSTRACT

Lung cancer is the leading cause of cancer deaths worldwide, with a 5-year survival rate of about 18%. Thus, there is a great need for novel therapeutic approaches to treat non-small-cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) have improved outcomes for a subset of patients, especially those with high programmed death-ligand 1 expression and/or high tumor mutational burden, but have failed in the majority of patients. Increasing evidence suggests that the estrogen signaling pathway may be a therapeutic target in metastatic NSCLC and that the estrogen pathway may play a role in sex-based responses to ICIs. This report will review the epidemiologic, preclinical and clinical data on the estrogen pathway in NSCLC, its implications in sex-based responses to ICIs and the potential use of antiestrogen therapy in combination with ICIs.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Carcinoma, Non-Small-Cell Lung/therapy , Estrogen Receptor Modulators/therapeutic use , Estrogens/metabolism , Immunotherapy/methods , Lung Neoplasms/therapy , Sex Factors , Animals , Carcinoma, Non-Small-Cell Lung/epidemiology , Carcinoma, Non-Small-Cell Lung/immunology , Clinical Trials as Topic , Drug Evaluation, Preclinical , Drug Therapy, Combination , Humans , Lung Neoplasms/epidemiology , Lung Neoplasms/immunology , Neoplasm Metastasis , Signal Transduction , Treatment Outcome
11.
Oral Oncol ; 89: 121-126, 2019 02.
Article in English | MEDLINE | ID: mdl-30732949

ABSTRACT

PURPOSE: To investigate the prognostic value of pre-treatment immune parameters including white blood cell count (WBC) and circulating lymphocyte count (CLC) among patients with oropharyngeal carcinoma treated by radiation therapy. METHODS AND MATERIALS: A total of 136 consecutive patients were treated by radiation therapy for locally advanced (stage III/IV) squamous cell carcinoma of the oropharynx with known human papillomavirus (HPV) status. Medical records were reviewed to identify patients with documented pre-treatment laboratory bloodwork. The Kaplan-Meier method and linear regression models were used to evaluate the association between pre-treatment CBC and CLC values with survival endpoints. RESULTS: One hundred and eleven patients satisfied inclusion criteria. Median age was 62 years (range, 22-91). Eighty-four patients were HPV-positive (76%) and 27 (24%) were HPV-negative. There was no difference in WBC and CLC mean values at baseline between HPV-positive and HV-negative (p > 0.05, for both). Trends were detected in the HPV-positive cohort favoring patients with higher CLC, with respect to 2-year local-regional control (93% vs. 82%, p = 0.06) and distant control (88% vs. 82%, p = 0.10) using the median CLC as cut-off. HPV-positive patients with CLC values in the lowest quartile had inferior local-regional control compared to those in the upper 3 quartiles (69% vs. 89%, p = 0.01). CONCLUSION: Low pre-treatment CLC was correlated with local-regional recurrence and distant failure among HPV-positive patients. These associations were not observed in the HPV-negative cohort.


Subject(s)
Oropharyngeal Neoplasms/immunology , Oropharyngeal Neoplasms/radiotherapy , Papillomaviridae/pathogenicity , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Oropharyngeal Neoplasms/pathology , Prognosis , Young Adult
12.
13.
Laryngoscope ; 128(10): 2345-2350, 2018 10.
Article in English | MEDLINE | ID: mdl-29573279

ABSTRACT

OBJECTIVE: The utility of fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to predict outcome has been well-established for patients undergoing definitive radiation in the initial management of head and neck cancer. However, the usefulness of this modality in the recurrent setting remains uncertain. We sought to evaluate the prognostic value of metabolic tumor parameters measured on FDG-PET in patients treated by reirradiation for recurrent head and neck cancer. METHODS: Thirty-four tumors occurring in 29 patients were reirradiated and were evaluable. The most common disease sites were the oropharynx (n = 9), oral cavity (N = 8), and nasopharynx (n = 6). Potential correlations of FDG-PET maximum standardized uptake value (SUV) and metabolic tumor volume (MTV) with survival endpoints were explored. Multivariate analysis was performed using Cox proportional hazard. RESULTS: The median MTV, SUV, and gross tumor volume, as delineated using the 50% SUVmax threshold, were 366 cc (range, 0-3,567 cc), 8.1 (range, 0-25), and 48.5 cc (range, 1-190 cc), respectively. On univariate analysis, both MTVs (as measured as a continuous variable and using the median value of 266 cc as cutoff) were predictive of decreased overall survival (P < 0.05 for both). A strong trend toward decreased progression-free survival (P = 0.05), in-field control (P = 0.06), and locoregional control (P = 0.07) was also observed with increasing MTV when analyzed as a continuous variable. Multi-variate analysis confirmed MTV as an independent predictor of mortality. CONCLUSION: The PET-derived parameter MTV may serve as a potentially valuable factor for risk stratification and for guiding treatment in future reirradiation trials. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:2345-2350, 2018.


Subject(s)
Head and Neck Neoplasms/diagnostic imaging , Head and Neck Neoplasms/radiotherapy , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Recurrence, Local/radiotherapy , Positron-Emission Tomography/methods , Re-Irradiation , Adult , Aged , Aged, 80 and over , Biopsy , Female , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Prognosis , Radiopharmaceuticals , Retrospective Studies , Survival Rate , Treatment Outcome
14.
Am J Otolaryngol ; 39(3): 257-260, 2018.
Article in English | MEDLINE | ID: mdl-29433815

ABSTRACT

PURPOSE: To evaluate the prognostic significance of human papillomavirus (HPV) status among patients treated by salvage radiation therapy for local-regional recurrences and second primary cancers of the head and neck arising in a previously irradiated field. METHODS AND MATERIALS: The medical records of 54 consecutive patients who underwent re-irradiation for squamous cell carcinoma of the head and neck occurring in a previously irradiated field were reviewed. Only patients with biopsy-proven evidence of recurrent disease that had previously been treated with doses of radiation therapy of at least 60 Gy were included. Determination of HPV status at the time of recurrence was performed by p16 immunohistochemistry. The median age at re-irradiation was 58.5 years (range, 27.9 to 81.5 years). Thirty patients (55.5%) were lifelong never-smokers. The Kaplan Meier method was used to calculate overall survival, progression-free survival, and local-regional control, and distant metastasis-free survival with comparisons between groups performed using the log-rank test. RESULTS: HPV status among tumors that were re-irradiated was as follows: 16 positive (29.7%); 7 negative (12.9%); 31 unknown (57.4%). The median overall survival in the entire cohort was 11.7 months (range, 8 to 27 months), with the 1-year and 2-year estimates of overall survival being 47.2% and 38.4%, respectively. A statistical trend was identified favoring patients with HPV-positive cancers with respect to the endpoints of overall survival (p = 0.06) and progression-free survival (p = 0.08) after re-irradiation when compared to the HPV-negative/unknown population. There was no significant difference in distant control between the two cohorts (p = 0.40). CONCLUSIONS: The favorable prognostic significance of HPV seemingly extends to patients treated by re-irradiation suggesting that this biomarker may be useful in risk stratification in this setting.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/virology , Head and Neck Neoplasms/radiotherapy , Neoplasm Recurrence, Local/radiotherapy , Neoplasms, Second Primary/radiotherapy , Papillomavirus Infections/complications , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Cohort Studies , Disease-Free Survival , Female , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/virology , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/virology , Neoplasms, Second Primary/mortality , Neoplasms, Second Primary/pathology , Neoplasms, Second Primary/virology , Papillomaviridae/isolation & purification , Papillomavirus Infections/pathology , Prognosis , Radiotherapy Dosage , Re-Irradiation/methods , Retrospective Studies , Risk Assessment , Statistics, Nonparametric , Survival Analysis , Treatment Outcome , Young Adult
15.
Int J Radiat Oncol Biol Phys ; 98(1): 83-90, 2017 05 01.
Article in English | MEDLINE | ID: mdl-28587056

ABSTRACT

PURPOSE: To study the tolerance of the brachial plexus to high doses of radiation exceeding historically accepted limits by analyzing human subjects treated with reirradiation for recurrent tumors of the head and neck. METHODS AND MATERIALS: Data from 43 patients who were confirmed to have received overlapping dose to the brachial plexus after review of radiation treatment plans from the initial and reirradiation courses were used to model the tolerance of this normal tissue structure. A standardized instrument for symptoms of neuropathy believed to be related to brachial plexus injury was utilized to screen for toxicity. Cumulative dose was calculated by fusing the initial dose distributions onto the reirradiation plan, thereby creating a composite plan via deformable image registration. The median elapsed time from the initial course of radiation therapy to reirradiation was 24 months (range, 3-144 months). RESULTS: The dominant complaints among patients with symptoms were ipsilateral pain (54%), numbness/tingling (31%), and motor weakness and/or difficulty with manual dexterity (15%). The cumulative maximum dose (Dmax) received by the brachial plexus ranged from 60.5 Gy to 150.1 Gy (median, 95.0 Gy). The cumulative mean (Dmean) dose ranged from 20.2 Gy to 111.5 Gy (median, 63.8 Gy). The 1-year freedom from brachial plexus-related neuropathy was 67% and 86% for subjects with a cumulative Dmax greater than and less than 95.0 Gy, respectively (P=.05). The 1-year complication-free rate was 66% and 87%, for those reirradiated within and after 2 years from the initial course, respectively (P=.06). CONCLUSION: The development of brachial plexus-related symptoms was less than expected owing to repair kinetics and to the relatively short survival of the subject population. Time-dose factors were demonstrated to be predictive of complications.


Subject(s)
Brachial Plexus Neuropathies/etiology , Brachial Plexus/radiation effects , Head and Neck Neoplasms/radiotherapy , Radiation Tolerance , Re-Irradiation , Adult , Aged , Brachial Plexus/diagnostic imaging , Female , Head and Neck Neoplasms/diagnostic imaging , Humans , Hypesthesia/etiology , Male , Middle Aged , Neoplasm Recurrence, Local/radiotherapy , Pain/etiology , Radiosurgery , Radiotherapy Dosage , Radiotherapy, Intensity-Modulated , Re-Irradiation/adverse effects , Retrospective Studies , Time Factors
16.
Food Res Int ; 96: 215-225, 2017 06.
Article in English | MEDLINE | ID: mdl-28528102

ABSTRACT

Homogenization applied to cheese milk has shown to increase lipolysis but its use is not spread as it can induce detrimental effects. The aim of this work was to assess the effect of low-pressure homogenization of the cream followed by pre-incubation of cheese milk on the composition, ripening index, lipolysis and volatile profiles of hard cooked cheeses. For that, control and experimental miniature Reggianito cheeses were made and analyzed during ripening (3, 45 and 90days). Homogenization had no impact on composition and proteolysis. An acceleration of the lipolysis reaction was clearly noticed in cheeses made with homogenized milk at the beginning of ripening, while both type of cheeses reached similar levels at 90days. We found the level of several compounds derived from fatty acid catabolism were noticeably influenced by the treatment applied: straight-chain aldehydes such as hexanal, heptanal and nonanal and methylketones from C5 to C9 were preferentially formed in experimental cheeses.


Subject(s)
Cheese/analysis , Cooking , Fatty Acids/metabolism , Lipolysis , Milk/metabolism , Volatile Organic Compounds/metabolism , Animals , Cattle , Cheese/microbiology , Food Handling/methods , Food Microbiology/methods , Hardness , Milk/microbiology , Proteolysis , Time Factors
17.
Oral Oncol ; 67: 46-51, 2017 04.
Article in English | MEDLINE | ID: mdl-28351580

ABSTRACT

PURPOSE: To evaluate a single-institutional experience with the use of re-irradiation for recurrent and new primary cancers of the head and neck. METHODS: The medical charts of 80 consecutive patients who underwent re-irradiation for local-regionally recurrent or second primary head and neck cancer between November 1998 and December 2015 were analyzed. Multivariate analysis was performed using Cox proportional hazard and logistic regression to determine predictors of clinical outcomes. RESULTS: Seventy-six of the 80 patients were evaluable. The median age was 57.5 (range 26.6-84.9); Intensity-modulated radiotherapy (IMRT) was used in 71 (93.4%) patients with a median dose of 60Gy. Thirty-one patients (40.8%) underwent salvage surgery before re-irradiation and 47 (61.8%) received concurrent systemic therapy. The median time interval between radiation courses was 25.3months (range 2-322months). The 2-year estimates of overall survival, progression free survival, locoregional control, and distant control were 51.0%, 31.3%, 36.8% and 68.3%, respectively. Patients who underwent salvage surgery prior to re-irradiation had significantly improved locoregional control, progression free survival, and overall survival (p<0.05, for all). On multivariate analysis, gross tumor volume (GTV) at re-irradiation and interval between radiation courses were associated with improved overall survival. Severe (grade⩾3) late complications were observed in 25 patients (32.8%). CONCLUSIONS: Re-irradiation for recurrent or second primary head and neck cancer is feasible and effective in select patients with head and neck cancer. The high observed rate of treatment-related morbidity highlights the continue challenges that accompany this approach.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Neoplasm Recurrence, Local/radiotherapy , Neoplasms, Second Primary/radiotherapy , Adult , Aged , Aged, 80 and over , Head and Neck Neoplasms/secondary , Humans , Middle Aged , Radiotherapy, Intensity-Modulated
18.
J Thorac Oncol ; 12(2): 293-301, 2017 02.
Article in English | MEDLINE | ID: mdl-27743888

ABSTRACT

INTRODUCTION: In the randomized trial of standard- versus high-dose chemoradiotherapy for locally advanced (LA) NSCLC (Radiation Therapy Oncology Group 0617), overall survival (OS) was worse in the high-dose arm. Although heart dose was suggested as a contributing factor, actionable parameters have not been established. We present an analysis of clinical and dosimetric parameters affecting OS in this patient population, focusing on heart dose. METHODS: Clinical data were collected on 416 patients with LA NSCLC treated at a single institution, with a subset of 333 available treatment plans recontoured using Radiation Therapy Oncology Group 0617 normal tissue guidelines. Toxicity and dosimetry data were analyzed for 322 patients; multivariate analysis was performed on 251 patients. Dosimetric parameters of radiation to tumor and organs at risk were analyzed with clinical data pertaining to OS, disease-free survival, and toxicity. RESULTS: Patients were treated with radiation therapy to prescribed doses of 50.0 to 84.9 Gy (median 66.0 Gy). Median follow-up was 14.5 months. Median OS was 16.8 months. The 1- and 2-year OS rates were 61.4% and 38.8%, respectively. On multivariate analysis, factors independently associated with worse OS were increasing heart V50 (volume receiving ≥50 Gy), heart volume, lung V5 (proportion of the lung structure [excluding the target volume]) receiving at least 5 Gy), bilateral mediastinal lymph node involvement, and lack of concurrent chemotherapy. When stratified by heart V50 less than 25% versus 25% or greater, the 1-year OS rates were 70.2% versus 46.8% and the 2-year OS rates were 45.9% versus 26.7% (p < 0.0001). Median heart V50 was significantly higher (20.8% versus 13.9%, p < 0.0001) for patients with cardiac toxicity with a Common Terminology Criteria for Adverse Events grade of 1 or higher. CONCLUSIONS: Heart dose is associated with OS and cardiac toxicity for patients with LA NSCLC treated with chemoradiotherapy.


Subject(s)
Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Squamous Cell/mortality , Chemoradiotherapy/mortality , Heart/physiopathology , Lung Neoplasms/mortality , Neoplasm Recurrence, Local/mortality , Organs at Risk/physiopathology , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/therapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Female , Follow-Up Studies , Heart/radiation effects , Humans , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapy , Neoplasm Staging , Organs at Risk/radiation effects , Prognosis , Radiometry , Radiotherapy Dosage , Radiotherapy, Intensity-Modulated/methods , Retrospective Studies , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...